Expansion readiness Zelluna is nearing clinical entry for its lead candidate ZI-MA4-1, signaling a potential need for CROs, CMOs, and manufacturing partners to support clinical trials and scale-up in the near term.

Manufacturing scalability The company highlights a scalable, cost-effective proprietary manufacturing process for TCR-NK cells, presenting opportunities for CDMOs and bioprocess experts to collaborate on large-scale production and supply chain optimization.

Strategic partnerships Past and ongoing collaborations with Catalent and Ultimovacs indicate openness to strategic partnerships, licensing, and co-development models that can accelerate go-to-market and broaden platform applications.

Global market positioning Norwegian base with an immunotherapy focus targeting solid tumors positions Zelluna to engage European and US life sciences ecosystems for funding, clinical development support, and international distribution strategies.

Talent and leadership Recent C-suite and board activity suggests a dynamic leadership transition and growth trajectory, signaling a potential need for senior advisory, fundraising support, and US market entry expertise to drive scale.